Participants were randomised to receive benzalkonium chloride-containing latanoprost (Xalatan) or preservative-free bimatoprost (Lumigan). Through this study, the investigators would like to analyze the impact of different antiglaucoma medications on ocular surface disease in glaucoma patients.
The purpose of our study is to assess the effect of antiglaucoma medication on ocular surface disease in glaucoma patients before and after treatment with different antiglaucoma medication. All included patients are newly diagnosed with glaucoma and received no previous antiglaucoma treatment. Medical records will be collected prospectively from Sep. 15th 2019 to Aug. 31st 2022. The symptoms and signs of ocular surface disease in each individual will be assessed with questionnaire and clinical exams, including the basal Schirmer's test, non-invasive tear film breakup time, meibography, and in vivo confocal microscopy before and at 1, 3, 6 months after treatment.
Study Type
OBSERVATIONAL
Enrollment
300
Lumigan PF: 0.03% bimatoprost (preservative-free) Xalatan: 0.005% latanoprost (containing 0.02% BAK as a preservative) All patients were instructed to use only the given study medication during the study period.
National Taiwan University Hospital
Taipei, Taiwan
RECRUITINGThe influence of glaucoma eye drops on ocular surface disease index (OSDI) in patients
Time frame: Change from Baseline OSDI at 1 month
The influence of glaucoma eye drops on ocular surface disease index (OSDI) in patients
Time frame: Change from Baseline OSDI at 4 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.